
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc. is advancing its clinical-stage pipeline with promising programs MZE829 and MZE782, which target chronic kidney disease with innovative, precision medicine approaches, enhancing its potential for accelerated regulatory approval based on strong Phase 2 and Phase 1 trial data. The company’s ability to demonstrate significant efficacy signals, such as a ≥30-35% reduction in broad AMKD for MZE829 and a robust pharmacodynamic profile for MZE782, positions it favorably in the competitive landscape of renal and cardiovascular diseases. Additionally, Maze’s comprehensive enrollment strategy and focus on leveraging genetic insights to expand its addressable market underscore its commercial attractiveness and long-term growth potential.
Bears say
Maze Therapeutics Inc. faces significant challenges related to its investigational drug, inaxaplin, which may inflate the perceived efficacy signals due to inherent risks associated with chronic kidney disease (CKD) and the complexities of patient treatment regimens. The company's pipeline, particularly focusing on MZE829 and MZE782, could encounter setbacks as low baseline proteinuria and substantial scarring in diabetic kidney disease (DKD) patients complicate treatment outcomes, leading to potential financial impacts. Furthermore, the evaluation of various surrogate endpoints suggests that any modest reductions in key biomarkers could result in significant downside risks and indicate systemic safety concerns potentially limiting the effectiveness and marketability of their therapies.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares